Characteristic | USC ( N = 15) | PTR ( N = 42) | P value | |
---|---|---|---|---|
Follow-up duration (months) | 13.4 (11.3 to 23.2) | 19.2 (12.4 to 28.9) | 0.232 | |
Age (years) | 63 (48 to 65) | 61.5 (54 to 70.5) | 0.568 | |
Sex | Male | 7 | 8 | 0.048 |
Female | 8 | 34 | ||
BMI (kg/m2) | 21.2 (16.9 to 25.5) | 21.4 (19.8 to 23.1) | 0.978 | |
Performance status | 0 | 14 | 39 | 1.00 |
1 | 1 | 3 | ||
≥2 | 0 | 0 | ||
ASA score | 1 | 3 | 10 | 0.949 |
2 | 11 | 29 | ||
3 | 1 | 3 | ||
4 | 0 | 0 | ||
Primary tumor site | Right colon | 1 | 13 | 0.005 |
Left colon | 3 | 18 | ||
Rectum | 11 | 11 | ||
KRAS status | Wild type | 6 | 24 | 0.368 |
Mutant or unknown | 9 | 18 | ||
CEA | 23.1 (4.1 to 60.3) | 41.5 (12.9 to 344) | 0.074 | |
Invasion depth | T2 | 0 | 1 | 0.337 |
T3 | 6 | 17 | ||
T4a | 9 | 20 | ||
T4b | 0 | 4 | ||
Lymph node metastasis | Negative | 1 | 5 | 1.00 |
Positive | 14 | 37 | ||
Sum of the longest diameters of metastases (mm) | 61 (46 to 150) | 75 (41.5 to 109) | 0.697 | |
Number of metastases | 17 (6 to 52) | 11.5 (5.5 to 28) | 0.309 | |
Number of organs with metastasis | 2 (1 to 2) | 2 (1 to 2) | 0.899 | |
Peritoneal dissemination | 2 (13.3%) | 7 (16.7%) | 1.00 | |
Total lines of chemotherapy | 2 (2 to 3) | 2 (1 to 3) | 1.00 | |
Use or any molecular target agents | 13 (86.7%) | 37 (88.1%) | 1.00 | |
Bevacizumab | 12 (80.0%) | 33 (78.6%) | 1.00 | |
Cetuximab and/or panitumumab* | 6 (100%) | 16 (66.7%) | 0.155 | |
Use of oxaliplatine combination | 14 (93.3%) | 36 (85.7%) | 0.66 | |
Use irinotecan combination | 12 (80.0%) | 26 (61.9%) | 0.339 | |
Conversion | 1 (6.7%) | 0 (0%) | 0.263 |